Parkinson's Disease

---

What is the evidence that butyrate is important in PD

Butyrate is a short-chain fatty acid produced when specific gut bacteria ferment dietary fiber, with major contributors including Faecalibacterium, Roseburia, and related taxa. In Parkinson’s disease (PD), one of the most reproducible microbiome findings is a reduction in short-chain-fatty-acid-producing bacteria, especially butyrate producers, together with lower fecal levels of butyrate and other SCFAs. This has been shown across multiple studies and meta-analyses, making a butyrate deficit one of the strongest functional signals emerging from the PD gut microbiome literature. In one human study, reduced fecal SCFAs in PD were also associated with worse clinical severity, linking the metabolite change to disease burden rather than to microbiome composition alone [5-6].

The importance of butyrate in PD is not simply that it is “low,” but that its normal functions are highly relevant to disease mechanisms. Butyrate is the primary fuel for colonocytes and helps maintain intestinal barrier integrity, mucus production, and tight-junction function. When butyrate levels fall, the gut barrier may become more permeable, allowing microbial products and inflammatory signals to access the circulation more readily. This is important in PD because intestinal permeability, gut inflammation, and altered microbiota-host interactions have all been reported in patients, supporting the idea that loss of butyrate may contribute to the gut dysfunction that often precedes or accompanies neurologic disease [7-8].

Butyrate is also relevant because it has potent anti-inflammatory and neuroactive properties. It can signal through free-fatty-acid receptors, inhibit histone deacetylases, and modulate gene expression in immune and neural cells. Experimental work suggests that butyrate can reduce inflammatory cytokine production, decrease microglial activation, influence blood-brain barrier function, and exert neuroprotective effects in PD-related models. Together, these findings support a biologically plausible link between reduced gut butyrate production and the processes thought to drive PD progression, including chronic inflammation, barrier dysfunction, and gut-brain axis disruption [5, 9].

So, the evidence that butyrate is important in PD comes from three converging lines: first, PD patients consistently show depletion of butyrate-producing microbes and reduced fecal butyrate; second, these changes correlate with symptom severity and other disease-associated gut abnormalities; and third, butyrate itself has known barrier-protective, anti-inflammatory, epigenetic, and neuroprotective functions that are highly relevant to PD pathogenesis. Taken together, this supports the idea that a chronic “butyrate deficit” is not just a biomarker of dysbiosis, but may be a mechanistically important feature of PD [5, 7-8].

Restoring the gut barrier and calming inflammation

Butyrate plays a central role in maintaining intestinal barrier integrity and regulating immune signaling at the gut interface. As the primary energy source for colonocytes, butyrate supports epithelial cell metabolism, promotes tight junction assembly, and stimulates the production of protective mucus by goblet cells. These processes help maintain a robust intestinal barrier that prevents microbial products—such as lipopolysaccharides (LPS), peptidoglycans, and other inflammatory molecules—from entering the systemic circulation. When butyrate levels decline, epithelial cells receive less metabolic support, tight junction proteins such as occludin and claudins are reduced, and the mucus layer can become thinner. The result is increased intestinal permeability, commonly referred to as a “leaky gut.”

Evidence suggests that this barrier dysfunction is highly relevant to Parkinson’s disease (PD). Several clinical and mechanistic studies have reported increased intestinal permeability, altered microbiota composition, and signs of intestinal inflammation in PD patients. These changes are frequently accompanied by reductions in butyrate-producing bacteria and lower fecal levels of short-chain fatty acids (SCFAs). Loss of these metabolites may weaken epithelial barrier function, allowing bacterial products to enter the circulation and trigger systemic immune responses that can ultimately influence neuroinflammation in the brain [10-12].

This process may create a self-reinforcing inflammatory loop. Reduced butyrate weakens intestinal barrier integrity, permitting microbial molecules and inflammatory mediators to escape the gut. These signals can activate immune responses both systemically and within the central nervous system, including the activation of microglia. Chronic neuroinflammation is believed to contribute to the progressive loss of dopaminergic neurons in PD, suggesting that gut-derived inflammatory signals may represent an important pathway linking intestinal dysbiosis to neurodegeneration [13-14]. 

Restoring butyrate levels therefore represents a promising strategy to interrupt this cycle. Approaches include increasing dietary fiber intake to stimulate endogenous microbial production, promoting the growth of butyrate-producing bacteria through microbiome-targeted interventions, or administering butyrate directly as a supplement. Preclinical studies support this therapeutic concept. In animal models of PD, including the MPTP model, administration of butyrate or other histone deacetylase inhibitors reduces microglial activation, lowers pro-inflammatory cytokine levels, and improves motor function while protecting dopaminergic neurons [13, 15].

Beyond its barrier-supporting effects, butyrate also acts as a signaling molecule that modulates immune responses and gene expression. As a histone deacetylase (HDAC) inhibitor, it can influence transcriptional programs involved in inflammation, cellular stress responses, and neuronal survival. Through these epigenetic and immunomodulatory mechanisms, butyrate may help shift the host environment toward a more anti-inflammatory and neuroprotective state.

Together, these findings suggest that restoring butyrate levels could simultaneously strengthen the gut barrier, dampen systemic inflammation, and reduce inflammatory signaling reaching the brain. Within the framework of the gut–brain axis, this positions butyrate not merely as a microbial metabolite but as a key mediator linking microbiome composition, intestinal health, immune regulation, and neurodegenerative disease processes [10-11, 13-15].

Direct neuroprotection and epigenetic effects

Beyond its roles in gut barrier maintenance and immune regulation, butyrate can directly influence neuronal health through epigenetic mechanisms. Butyrate functions as a histone deacetylase (HDAC) inhibitor, allowing it to modify chromatin structure and regulate gene expression in neurons and glial cells. By inhibiting HDAC activity, butyrate promotes transcription of genes involved in neuronal survival, stress resistance, and synaptic plasticity. These epigenetic effects are particularly relevant in PD, where dysregulated gene expression and impaired cellular stress responses contribute to dopaminergic neuron vulnerability.

Experimental studies support a direct neuroprotective role for butyrate in PD models. In dopaminergic neuronal cultures overexpressing either wild-type or mutant α-synuclein, sodium butyrate has been shown to rescue neurons from α-synuclein–induced toxicity. These protective effects appear to involve normalization of stress-response pathways and restoration of protective gene expression programs disrupted by α-synuclein aggregation. By altering transcriptional networks that regulate mitochondrial function, oxidative stress responses, and protein homeostasis, butyrate may counteract several of the cellular stresses that drive dopaminergic neuron degeneration [15-16].

Evidence from animal models further supports these neuroprotective properties. In MPTP mouse models of PD, administration of sodium butyrate improves motor behavior, increases movement speed and limb strength, and protects dopaminergic neurons in the substantia nigra. One study linked these benefits to modulation of the circadian clock Bmal1, which regulates downstream pathways involved in neuronal resilience and metabolic homeostasis. Restoration of these transcriptional programs appears to reduce oxidative stress and inflammation while promoting neuronal survival [17-18].

Importantly, the beneficial actions of butyrate may extend beyond classical motor circuits. In several experimental systems, butyrate enhances synaptic plasticity, improves memory formation, and promotes neurotrophic signaling pathways. These findings suggest that butyrate’s HDAC-inhibitory activity can broadly influence neural network function and adaptive plasticity. Within the context of PD, such pro-plasticity and pro-survival effects could help preserve neuronal circuitry and slow functional decline.

Taken together, these findings indicate that butyrate may influence PD progression through multiple complementary mechanisms: strengthening the intestinal barrier, suppressing systemic inflammation, and directly promoting neuronal survival through epigenetic regulation of gene expression. This combination of peripheral and central effects positions butyrate as a potentially important mediator linking the gut microbiome to neurodegenerative disease processes.

Benefits for sleep, cognition, and non-motor symptoms

In PD, non-motor symptoms—including sleep disturbances, cognitive decline, fatigue, depression, and autonomic dysfunction—often have a greater impact on quality of life than the classical motor features. Increasing evidence suggests that the gut microbiome and its metabolites, particularly butyrate, may influence these symptoms through gut–brain signaling pathways. Because butyrate affects inflammation, neuronal signaling, and circadian biology, restoring butyrate levels has emerged as a potential strategy for addressing several non-motor manifestations of PD.

Sleep disruption is among the most common non-motor symptoms in PD and includes insomnia, fragmented sleep, REM sleep behavior disorder, and altered circadian rhythms. Experimental work suggests that microbiome-derived metabolites can influence sleep architecture through immune, metabolic, and neurochemical pathways. In preclinical PD models, oral butyrate supplementation has been reported to improve abnormal sleep patterns and restore aspects of circadian regulation, supporting the idea that microbial metabolites can influence central sleep-wake circuits through the gut–brain axis. These findings are consistent with broader research showing that SCFAs modulate neuroinflammation and neuronal activity in brain regions involved in sleep regulation [13, 19].

Cognitive impairment is another major concern in PD, ranging from mild cognitive dysfunction to Parkinson’s disease dementia. Butyrate may influence cognition through several mechanisms, including its anti-inflammatory effects, promotion of synaptic plasticity, and epigenetic regulation of genes involved in neuronal survival and memory formation. In multiple neurological disease models, butyrate and other HDAC inhibitors enhance learning and memory performance while increasing expression of neurotrophic factors that support neuronal connectivity. These findings have prompted clinical interest in butyrate-based therapies aimed at improving cognitive outcomes in neurodegenerative diseases [15, 20].

This translational interest is beginning to extend into human studies. Early-phase clinical trials are now exploring tributyrin, a prodrug that releases butyrate, as a potential therapy for patients with PD and cognitive impairment. These trials aim to evaluate whether increasing systemic butyrate levels can improve cognitive performance, gait stability, and balance while reducing inflammatory markers associated with disease progression. Although results are still pending, the rationale for these studies is supported by strong mechanistic and preclinical evidence linking SCFAs to neuroinflammation, neuronal resilience, and gut–brain signaling.

One has to be cautious about tributyrin. An important limitation of this compound should be noted. Tributyrin is rapidly hydrolyzed by gastric and pancreatic lipases in the stomach and small intestine, releasing free butyrate that is absorbed systemically before it reaches the colon. This pharmacokinetic profile differs substantially from the physiological production of butyrate, which normally occurs in the large intestine through microbial fermentation of dietary fibers and results in high local concentrations that directly support colonocyte metabolism, epithelial barrier integrity, and mucosal immune regulation. As a result, tributyrin primarily increases circulating butyrate levels rather than restoring the luminal colonic butyrate pool that is central to gut barrier maintenance. This distinction is important when interpreting therapeutic studies, as systemic delivery may reproduce some signaling effects of butyrate but may not fully replicate the local intestinal functions of microbiome-derived butyrate. The implications of these delivery differences—and potential strategies to better target butyrate activity to the colon—are discussed in more detail in another section.

More broadly, observational studies of PD patients consistently report altered SCFA profiles, including reduced levels of butyrate-producing bacteria and lower fecal or plasma SCFAs. In several cohorts, these metabolic changes correlate with both motor severity and non-motor symptoms, suggesting that SCFA deficiency may contribute to the systemic features of the disease. While most human studies measure total SCFA patterns rather than butyrate alone, the consistent depletion of butyrate-producing taxa strengthens the hypothesis that restoring this metabolite could have therapeutic benefit [10-11].

Taken together, these findings suggest that butyrate may influence multiple domains of PD pathology beyond motor circuits, including sleep regulation, cognitive function, and systemic inflammation. By modulating gut–brain communication, immune signaling, and neuronal gene expression, butyrate-based interventions may offer a strategy to address the multi-system nature of Parkinson’s disease, potentially improving both neurological and quality-of-life outcomes.

BACK

References

1. Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021 Mar 10;7(1):27. doi: 10.1038/s41531-021-00156-z. PMID: 33692356; PMCID: PMC7946946.

2. Abreu AE, Empadinhas N, Cardoso SM. Unveiling Butyrate as a Parkinson's Disease Therapy. Neurosci Bull. 2026 Jan;42(1):233-246. doi: 10.1007/s12264-025-01498-x. Epub 2025 Oct 15. PMID: 41091367; PMCID: PMC12789372.

3. Fang Chi, Kun Chen, Yue Yin, Janetta R Hakovirta, Per E J Saris, From dysbiosis to dysfunction: specific gut microbes and metabolites in the pathogenesis of Parkinson’s disease, Sustainable Microbiology, Volume 3, Issue 1, 2026, qvag002, https://doi.org/10.1093/sumbio/qvag002

4. Hou Y, Li X, Liu C, Zhang M, Zhang X, Ge S, Zhao L. Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease. Exp Gerontol. 2021 Jul 15;150:111376. doi: 10.1016/j.exger.2021.111376. Epub 2021 Apr 24. PMID: 33905875.

5. Xie A, Ensink E, Li P, Gordevičius J, Marshall LL, George S, Pospisilik JA, Aho VTE, Houser MC, Pereira PAB, Rudi K, Paulin L, Tansey MG, Auvinen P, Brundin P, Brundin L, Labrie V, Scheperjans F. Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms. Mov Disord. 2022 Aug;37(8):1644-1653. doi: 10.1002/mds.29128. Epub 2022 Jun 20. PMID: 35723531; PMCID: PMC9545646.

6. Chen SJ, Chen CC, Liao HY, Lin YT, Wu YW, Liou JM, Wu MS, Kuo CH, Lin CH. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease. Neurology. 2022 Feb 22;98(8):e848-e858. doi: 10.1212/WNL.0000000000013225. Epub 2022 Jan 7. PMID: 34996879; PMCID: PMC8883514.

7. Chen SJ, Chen CC, Liao HY, Lin YT, Wu YW, Liou JM, Wu MS, Kuo CH, Lin CH. Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease. Neurology. 2022 Feb 22;98(8):e848-e858. doi: 10.1212/WNL.0000000000013225. Epub 2022 Jan 7. PMID: 34996879; PMCID: PMC8883514.

8. Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, Hertzberg V, Auvinen P, Tansey MG, Scheperjans F. Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson's disease. Mol Neurodegener. 2021 Feb 8;16(1):6. doi: 10.1186/s13024-021-00427-6. PMID: 33557896; PMCID: PMC7869249.

9. Elford JD, Becht N, Garssen J, Kraneveld AD, Perez-Pardo P. Buty and the beast: the complex role of butyrate in Parkinson's disease. Front Pharmacol. 2024 Apr 17;15:1388401. doi: 10.3389/fphar.2024.1388401. PMID: 38694925; PMCID: PMC11061429.

10. Scheperjans F, Aho V, Pereira PA, Koskinen K, Paulin L, Pekkonen E, Haapaniemi E, Kaakkola S, Eerola-Rautio J, Pohja M, Kinnunen E, Murros K, Auvinen P. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord. 2015 Mar;30(3):350-8. doi: 10.1002/mds.26069. Epub 2014 Dec 5. PMID: 25476529.

11. Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, Faßbender K, Schwiertz A, Schäfer KH. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. Parkinsonism Relat Disord. 2016 Nov;32:66-72. doi: 10.1016/j.parkreldis.2016.08.019. Epub 2016 Aug 26. PMID: 27591074.

12. Keshavarzian A, Green SJ, Engen PA, Voigt RM, Naqib A, Forsyth CB, Mutlu E, Shannon KM. Colonic bacterial composition in Parkinson's disease. Mov Disord. 2015 Sep;30(10):1351-60. doi: 10.1002/mds.26307. Epub 2015 Jul 16. PMID: 26179554.

13. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF, Keshavarzian A, Shannon KM, Krajmalnik-Brown R, Wittung-Stafshede P, Knight R, Mazmanian SK. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. Cell. 2016 Dec 1;167(6):1469-1480.e12. doi: 10.1016/j.cell.2016.11.018. PMID: 27912057; PMCID: PMC5718049.

14. Borghammer P, Van Den Berge N. Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. J Parkinsons Dis. 2019;9(s2):S281-S295. doi: 10.3233/JPD-191721. PMID: 31498132; PMCID: PMC6839496.

15. Liu J, Wang F, Liu S, Du J, Hu X, Xiong J, Fang R, Chen W, Sun J. Sodium butyrate exerts protective effect against Parkinson's disease in mice via stimulation of glucagon like peptide-1. J Neurol Sci. 2017 Oct 15;381:176-181. doi: 10.1016/j.jns.2017.08.3235. Epub 2017 Aug 24. PMID: 28991675.

16. Shukla S, Tekwani BL. Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. Front Pharmacol. 2020 Apr 24;11:537. doi: 10.3389/fphar.2020.00537. PMID: 32390854; PMCID: PMC7194116.

17. Kanan MF, Sheehan PW, Haines JN, Gomez PG, Dhuler A, Nadarajah CJ, Wargel ZM, Freeberg BM, Nelvagal HR, Izumo M, Takahashi JS, Cooper JD, Davis AA, Musiek ES. Neuronal deletion of the circadian clock gene Bmal1 induces cell-autonomous dopaminergic neurodegeneration. JCI Insight. 2024 Jan 23;9(2):e162771. doi: 10.1172/jci.insight.162771. PMID: 38032732; PMCID: PMC10906231.

18. Duan WX, Xie WY, Ying C, Fen W, Cheng XY, Mao CJ, Liu JY, Liu CF. Butyrate improves abnormal sleep architecture in a Parkinson's disease mouse model via BDNF/TrkB signaling. NPJ Parkinsons Dis. 2025 Jun 19;11(1):175. doi: 10.1038/s41531-025-01029-5. PMID: 40537481; PMCID: PMC12179271.

19. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K. The role of short-chain fatty acids in microbiota-gut-brain communication. Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):461-478. doi: 10.1038/s41575-019-0157-3. PMID: 31123355.

20. Sharma S, Taliyan R. Targeting histone deacetylases: a novel approach in Parkinson's disease. Parkinsons Dis. 2015;2015:303294. doi: 10.1155/2015/303294. Epub 2015 Jan 28. PMID: 25694842; PMCID: PMC4324954.